Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients—A Retrospective Single-Center AnalysisAlexander Nikoloudis, Johannes Clausen, Ines Julia Neumann et al.|Vaccines|2023Cited by 10
Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous RecipientsAlexander Nikoloudis, Johannes Clausen, Dagmar Wipplinger et al.|Transplantation and Cellular Therapy|2021Cited by 7
Adverse impact of a high<scp>CD4</scp>/<scp>CD8</scp>ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or post‐transplant cyclophosphamide‐based graft versus host disease prophylaxisAlexander Nikoloudis, Johannes Clausen, Veronika Buxhofer‐Ausch et al.|European Journal Of Haematology|2023Cited by 5
Impact of the Recipient’s Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell TransplantationAlexander Nikoloudis, Johannes Clausen, Veronika Buxhofer‐Ausch et al.|Cells|2023Cited by 5
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center ExperienceIrene Straßl, Johannes Clausen, Alexander Nikoloudis et al.|Cancers|2023Cited by 3